FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:840 February 19, 2004 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Kupper, T. S. PubMed Citation

To the Editor: I would like to correct an error in the Perspective by Kupper (Nov. 20 issue)¹ on immunologic targets in psoriasis. Dr. Kupper indicated that etanercept (Enbrel), a tumor necrosis factor (TNF-)–receptor fusion protein, has demonstrated efficacy in inflammatory bowel disease. In fact, in the most authoritative published experience with etanercept in the treatment of inflammatory bowel disease (a randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Crohn's disease), the drug was shown to be ineffective,² and it does not have marketing approval for any indication in inflammatory bowel disease.

Suzanne B. Travers, M.D.
Centocor
Malvern, PA . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.